XenaCare Holdings Announces National Print Advertising Campaign for Cobroxin, a Treatment for Moderate to Severe (Stage 2) Pain

XenaCare Holdings Announced That Its National Print Advertising Campaign for Cobroxin, the First Clinically Proven, Over-the-Counter Treatment for Moderate to Severe (Stage 2) Chronic Pain, is Scheduled to Begin in November and Will Run in Arthritis Today, Prevention, Health, Star, Woman's World, Soap Opera, and Self Magazines

• Press Release
• Source: XenaCare Holdings, Inc.
• On 9:00 am EDT, Thursday September 3, 2009

DELRAY BEACH, Fla.--(BUSINESS WIRE)--XenaCare Holdings, Inc. (OTCBB: XCHO - News), a company specializing in the marketing and retail distribution of consumer healthcare products, has announced today that it will begin its national print advertising campaign for Cobroxin in November. The campaign, which is budgeted at approximately $550,000, is scheduled to run through December and will appear in Arthritis Today, Prevention, Health, Star, Woman's World, Soap Opera, and Self magazines.

Related Quotes

Symbol	Price	Change
NPHC.OB	0.43	0.00

{"s" : "nphc.ob,xcho.ob","k" : "c10,l10,p20,t10","o" : "","j" : ""}

“This advertising campaign represents the first of several national campaigns we plan to roll out as we introduce Cobroxin through national retailers in the coming months,” explained Frank Rizzo, President of XenaCare Holdings, Inc. “In addition to print advertising, we are also finalizing online marketing campaigns and television commercials,” he concluded.

Cobroxin, which was developed by Nutra Pharma Corporation (OTCBB: NPHC - News), is the first opiate and acetaminophen-free pain reliever available as an over-the-counter formulation that is clinically proven to treat moderate to severe (Stage 2) chronic pain. In August, Nutra Pharma granted XenaCare Holdings the exclusive license for marketing and distributing Cobroxin throughout the United States.

About XenaCare Holdings

XenaCare Holdings, Inc. engages in the formulation, marketing, and distribution of nutrition supplement products primarily in the United States. Its clinical products include XenaCor, which supports the lowering of serum cholesterol, C-reactive protein, and homocysteine levels to support cardiovascular health; XenaTri for lowering triglycerides and raising HDL to support cardiovascular health; and XenaZyme Plus that increases the body’s oxygen carrying capacities designed to support digestion. XenaCare’s clinical products also comprise body replenishment products. In addition, the company offers formulations for the lifestyle performance market, which consists of sports line for athletes, including SunPill that is formulated to protect the skin when exposed to damaging ultraviolet rays. XenaCare markets its products through the Internet, pharmacies, and doctors offices. The company was founded in 2001 and is based in Delray Beach, Florida.

http://www.XenaCareHoldings.com

http://www.Cobroxin.com

SEC Disclaimer

This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in XenaCare's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). Announcing the Cobroxin national print advertising campaign should not be construed as an indication in any way whatsoever of the value of the Company or its common stock. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

XenaCare Holdings, Inc.
Frank Rizzo, 561-496-6676
FRizzo@XenaCare.com